Lucid Diagnostics (LUCD) Stock Statistics & Valuation Metrics

Lucid Diagnostics has a market cap or net worth of $140.65M. The enterprise value is $28.72M.

Lucid Diagnostics has 108,194,610 shares outstanding. The number of shares has decreased by -2.65% in one year.

Lucid Diagnostics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -30.33%.

The current PE Ratio of Lucid Diagnostics is -0.91. Lucid Diagnostics’s PEG ratio is >-0.01.

In the last 12 months, Lucid Diagnostics had revenue of 4.35M and earned -45.53M in profits. Earnings per share was -0.75.

In the last 12 months, operating cash flow was -12.50B and capital expenditures -609.00K, giving a free cash flow of -12.50B billion.

Lucid Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Lucid Diagnostics upcoming earnings date is Aug 18, 2025, TBA Not Confirmed.

Lucid Diagnostics as a current ratio of 1.07K, with Debt / Equity ratio of 8.67%

In the past 12 months, Lucid Diagnostics has paid 7.50B in taxes.

Lucid Diagnostics EV to EBITDA ratio is -0.91, with an EV/FCF ratio of -0.90.

Lucid Diagnostics has $25.24B in cash and marketable securities with $35.27B in debt, giving a net cash position of $10.03B billion.

Gross margin is -858.62%, with operating margin of -1059.64%, and net profit margin of -1047.61%.

The average price target for Lucid Diagnostics is $3.79, which is 11.43% higher than the current price. The consensus rating is Strong Buy